Post‐transfusion platelet responses in critically ill cancer patients with hypoproliferative thrombocytopenia

BACKGROUND Platelet transfusion is aimed at increasing platelet counts to prevent or treat bleeding. Critically ill cancer patients with hypoproliferative thrombocytopenia are high consumers of blood products. We herein described their post‐transfusion platelet responses in the intensive care unit (...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2020-02, Vol.60 (2), p.275-284
Main Authors: Baron, Elodie, Charpentier, Julien, François, Anne, Ben Hadj Amor, Habib, Habr, Bassem, Cariou, Alain, Chiche, Jean‐Daniel, Mira, Jean‐Paul, Jamme, Matthieu, Pène, Frédéric
Format: Article
Language:English
Subjects:
ABO system
Antibiotics
Bleeding
Blood platelets
Body mass
Body mass index
Body size
Cancer
Enlargement
Fever
Hematology
Human health and pathology
Life Sciences
Platelets
Spleen
Thermal resistance
Thrombocytopenia
Transfusion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Platelet transfusion is aimed at increasing platelet counts to prevent or treat bleeding. Critically ill cancer patients with hypoproliferative thrombocytopenia are high consumers of blood products. We herein described their post‐transfusion platelet responses in the intensive care unit (ICU) and analyzed the determinants of poor post‐transfusion increments. STUDY DESIGN AND METHODS This was a single‐center 9‐year (2009‐2017) retrospective observational study. Patients with malignancies and presumed or proven hypoproliferative thrombocytopenia who had received at least one platelet transfusion in the ICU were included. Poor post‐transfusion platelet increments were defined as body surface‐adjusted corrected count increment (CCI) 
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.15596